Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 74
Filter
1.
Nucl Med Commun ; 41(11): 1218-1220, 2020 Nov.
Article in English | MEDLINE | ID: mdl-32925830

ABSTRACT

Radioiodine therapy using oral administration of Iodine-131 (I) is a widespread employed strategy for the treatment of hyperthyroidism and thyroid cancer. Such a therapy requires well-trained staff, equipment and procedures regarding radiation safety. The aims of this work are to report an incidental experience of radioprotection with a 370 MBq sodium [I] iodide capsule, which arose following vomiting one minute after the oral administration in a nuclear medicine department and assessment of capsule leakage in a stomach like environment by in vitro experiment. Measurements of the radiation dose rate at the different steps of the decontamination procedure were performed and management of the situation described. Dose rate in vomit was 113 µSv/h [directional dose equivalent H'(0.07)] after capsule withdrawal and was decreased by 10 times after the first decontamination attempt. To evaluate the I release following administration to the patient, an in vitro experiment was designed to recap capsules degradation in a stomach like environment including acidic solution (pH 1) and temperature at 35-37°c. A significant release of I (<6%) was observed in the first 2 min of the in vitro experiment. Sodium [I] iodide capsules disruption occurred at 150 s for capsule 1 and 133 s for capsule 2. Incidental contamination with I in the clinics is of important concern in nuclear medicine and precautions that allow optimization and pertinent management of the situation should be known by the nuclear medicine and radioprotection community.


Subject(s)
Drug Contamination , Iodine Radioisotopes , Sodium Iodide/administration & dosage , Accidents , Administration, Oral , Drug Contamination/prevention & control , Hydrogen-Ion Concentration , Radiation Protection , Temperature
2.
Appl Radiat Isot ; 139: 251-255, 2018 Sep.
Article in English | MEDLINE | ID: mdl-29870920

ABSTRACT

We proposed use of astatine-210 in preclinical study. Astatine-210 has higher yield of production and is easier to quantify than astatine-211. We produced astatine-210 with Bi target and 40 MeV alpha beam accelerated by cyclotron, free astatine-210 was separated and injected to normal rats. Three male rats (blocking group) were injected non-radioactive iodide before injection of astatine-210. Compared with the control group, the astatine-210 accumulations in the blocking group decreased to 24% in the thyroid.


Subject(s)
Astatine/administration & dosage , Astatine/pharmacokinetics , Sodium Iodide/administration & dosage , Alpha Particles/adverse effects , Alpha Particles/therapeutic use , Animals , Astatine/isolation & purification , Male , Radiation Protection , Rats , Rats, Wistar , Thyroid Gland/metabolism , Thyroid Gland/radiation effects , Tissue Distribution
3.
J Vet Intern Med ; 32(1): 516-524, 2018 Jan.
Article in English | MEDLINE | ID: mdl-29377356

ABSTRACT

BACKGROUND: The prevention of bovine respiratory disease complex (BRD) in beef cattle is important to maintaining health and productivity of calves in feeding operations. OBJECTIVE: Determine whether BRD bacterial and viral pathogens are susceptible to the lactoperoxidase/hydrogen peroxide/iodide (LPO/H2 O2 /I- ) system in vitro and to determine whether the oral administration of sodium iodide (NaI) could achieve sufficient concentrations of iodine (I) in the respiratory secretions of weaned beef calves to inactivate these pathogens in vivo. ANIMALS: Sixteen weaned, apparently healthy, commercial beef calves from the University of Missouri, College of Veterinary Medicine teaching herd. METHODS: In vitro viral and bacterial assays were performed to determine susceptibility to the LPO/H2 O2 /I- system at varying concentrations of NaI. Sixteen randomly selected, healthy crossbred beef weanlings were administered 70 mg/kg NaI, or water, orally in a blinded, placebo-controlled trial. Blood and nasal secretions were collected for 72 hours and analyzed for I- concentration. RESULTS: Bovine herpesvirus-1, parainfluenza-3, Mannheimia haemolytica and Bibersteinia trehalosi were all inactivated or inhibited in vitro by the LPO/H2 O2 /I- reaction. Oral administration of NaI caused a marked increase in nasal fluid I concentration with a Cmax  = 181 (1,420 µM I), T12 , a sufficient concentration to inactivate these pathogens in vitro. CONCLUSIONS AND CLINICAL IMPORTANCE: In vitro, the LPO/H2 O2 /I- system inactivates and inhibits common pathogens associated with BRD. The administration of oral NaI significantly increases the I concentration of nasal fluid indicating that this system might be useful in preventing bovine respiratory infections.


Subject(s)
Bovine Respiratory Disease Complex/prevention & control , Nasal Mucosa/chemistry , Sodium Iodide/pharmacology , Administration, Oral , Animals , Bovine Respiratory Disease Complex/microbiology , Bovine Respiratory Disease Complex/virology , Cattle , Herpesvirus 1, Bovine/drug effects , Hydrogen Peroxide/chemistry , Iodine/analysis , Lactoperoxidase/metabolism , Mannheimia haemolytica/drug effects , Nasal Mucosa/microbiology , Nasal Mucosa/virology , Parainfluenza Virus 3, Human/drug effects , Pasteurellaceae/drug effects , Sodium Iodide/administration & dosage , Sodium Iodide/analysis
5.
Thyroid ; 26(10): 1488-1498, 2016 10.
Article in English | MEDLINE | ID: mdl-27461375

ABSTRACT

BACKGROUND: Iodine is essential for thyroid hormone synthesis and is an important regulator of thyroid function. Chronic iodine deficiency leads to hypothyroidism, but iodine excess also impairs thyroid function causing hyperthyroidism, hypothyroidism, and/or thyroiditis. This study aimed to investigate the underlying mechanisms by which exposure to chronic iodine excess impairs pituitary-thyroid axis function. METHODS: Male Wistar rats were treated for two months with NaI (0.05% and 0.005%) or NaI+NaClO4 (0.05%) dissolved in drinking water. Hormone levels, gene expression, and thyroid morphology were analyzed later. RESULTS: NaI-treated rats presented high levels of iodine in urine, increased serum thyrotropin levels, slightly decreased serum thyroxine/triiodothyronine levels, and a decreased expression of the sodium-iodide symporter, thyrotropin receptor, and thyroperoxidase mRNA and protein, suggesting a primary thyroid dysfunction. In contrast, thyroglobulin and pendrin mRNA and protein content were increased. Kidney and liver deiodinase type 1 mRNA expression was decreased in iodine-treated rats. Morphological studies showed larger thyroid follicles with higher amounts of colloid and increased amounts of connective tissue in the thyroid of iodine-treated animals. All these effects were prevented when perchlorate treatment was combined with iodine excess. CONCLUSIONS: The present data reinforce and add novel findings about the disruption of thyroid gland function and the compensatory action of increased thyrotropin levels in iodine-exposed animals. Moreover, they draw attention to the fact that iodine intake should be carefully monitored, since both deficient and excessive ingestion of this trace element may induce pituitary-thyroid axis dysfunction.


Subject(s)
Gene Expression Regulation/drug effects , Iodine/poisoning , Pituitary Gland/drug effects , Poisoning/physiopathology , Thyroid Gland/drug effects , Thyroiditis/etiology , Animals , Antidotes/therapeutic use , Iodide Peroxidase/antagonists & inhibitors , Iodide Peroxidase/genetics , Iodide Peroxidase/metabolism , Iodine/chemistry , Iodine/urine , Male , Perchlorates/therapeutic use , Pituitary Gland/metabolism , Pituitary Gland/pathology , Pituitary Gland/physiopathology , Poisoning/metabolism , Poisoning/pathology , Poisoning/prevention & control , RNA, Messenger/metabolism , Rats, Wistar , Receptors, Thyrotropin/antagonists & inhibitors , Receptors, Thyrotropin/genetics , Receptors, Thyrotropin/metabolism , Renal Elimination , Sodium Compounds/therapeutic use , Sodium Iodide/administration & dosage , Symporters/antagonists & inhibitors , Symporters/genetics , Symporters/metabolism , Thyroid Gland/metabolism , Thyroid Gland/pathology , Thyroid Gland/physiopathology , Thyrotropin/blood , Thyrotropin/metabolism , Thyroxine/blood , Thyroxine/metabolism , Toxicity Tests, Chronic , Toxicokinetics , Triiodothyronine/blood , Triiodothyronine/metabolism
6.
Thyroid ; 26(3): 441-8, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26857905

ABSTRACT

BACKGROUND: Although radioactive iodine (RAI) imaging/therapy is one of the earliest applications of theranostics, there remain a number of unresolved clinical questions as to the optimization of diagnostic techniques/protocols and improvements in patient-specific treatment planning strategies. The objectives of this study were to determine the imaging characteristics and clinical feasibility of (124)I positron emission tomography/computed tomography (PET/CT) for the determination of extent of disease and evaluation of RAI kinetics in its physiologic and neoplastic distribution in patients with differentiated thyroid cancer (DTC). METHODS: The study was designed as a prospective phase II diagnostic trial of patients with confirmed DTC. Following adequate preparation, patients received 2 mCi (124)I in liquid form and sequential whole-body PET/CT imaging was performed at five time points (2-4 h, 24 ± 6 h, 48 ± 6 h, 72 ± 6 h, and 96 ± 6 h post-administration). All patients who had (124)I imaging subsequently underwent RAI treatment with (131)I, with administered activities ranging from 100 to 300 mCi. Post-treatment scans were obtained 5-7 days after RAI treatment. A by-patient and by-lesion analysis of the (124)I images was performed and compared with the post-treatment (131)I scans as well as F-18 FDG PET/CT images. Quantitative image analysis was also performed to determine the total functional volume (mL), activity per functional volume (µCi/mL), and cumulated activity (µCi/h) for remnants, salivary glands, and nodal metastases. RESULTS: Fifteen patients (6 women; Mage = 57 years; range 29-91 years) were enrolled into the study. Forty-six distinct lesions were identified in these 15 patients on (124)I PET/CT images, with a sensitivity of 92.5%. In addition, (124)I identified 22.5% more foci of RAI-avid lesions compared with the planar (131)I post-treatment scans. This study demonstrates different kinetic profiles for normal thyroid remnants (peaked at 24 h with mono-exponential clearance), salivary glands (peaked at 4 h with bi-exponential clearance), and metastatic lesions (protracted retention), as well as individual variations in functional volumes and thus cumulated activities. CONCLUSIONS: (124)I PET/CT is a valuable clinical imaging tool/agent, both in determining the extent of disease in the setting of metastatic DTC and in the functional volumetric and kinetic evaluation of target lesions.


Subject(s)
Cell Differentiation , Iodine Radioisotopes/pharmacokinetics , Positron Emission Tomography Computed Tomography , Radiopharmaceuticals/pharmacokinetics , Sodium Iodide/pharmacokinetics , Thyroid Neoplasms/diagnostic imaging , Adult , Aged , Aged, 80 and over , Feasibility Studies , Female , Humans , Iodine Radioisotopes/administration & dosage , Male , Middle Aged , Neoplasm Metastasis , Predictive Value of Tests , Prognosis , Prospective Studies , Radiopharmaceuticals/administration & dosage , Sodium Iodide/administration & dosage , Thyroid Neoplasms/metabolism , Thyroid Neoplasms/pathology , Tissue Distribution
7.
J Biol Regul Homeost Agents ; 30(4): 1141-1145, 2016.
Article in English | MEDLINE | ID: mdl-28078866

ABSTRACT

The aim of this prospective pilot study was to evaluate the efficiency of an oral hygiene protocol, in combination with a solution of sodium iodide associated to salicylic acid (SISA), in patients affected by desquamative gingivitis (DG). Twenty patients not totally responding to conventional topical therapies, were selected. They received oral hygiene instructions with non-surgical periodontal therapy in a 21-day cohort study (during 3 weekly appointments). The SISA was used at the end of each session, with an impregnated gauze (with 5 ml of the solution) applied for 15 minutes for the upper jaw, and for a further 15 minutes with a new gauze for the lower. Evaluated clinical outcome variables included the full mouth plaque (FMPS) and bleeding (FMBS) scores, probing depth, patient related outcome and clinical gingival signs. Two months after concluding the planned protocol, a statistically significant reduction was observed for FMPS (P=0.032), FMBS (P=0.038), reported pain (P=0.000) and gingival clinical improvement (P=0.005). Topical application of SISA and professional oral hygiene procedures are connected with improvement of gum status, and decrease of related pain in subjects affected by severe DG.


Subject(s)
Dental Care/methods , Gingivitis/therapy , Keratolytic Agents/administration & dosage , Oral Hygiene/methods , Salicylic Acid/administration & dosage , Sodium Iodide/administration & dosage , Administration, Topical , Dental Plaque Index , Female , Humans , Male , Middle Aged , Pilot Projects , Prospective Studies
8.
Med Phys ; 43(10): 5279-5287, 2016 Oct.
Article in English | MEDLINE | ID: mdl-28105713

ABSTRACT

PURPOSE: To investigate the possible differences between SPECT/CT based whole-remnant and maximum-voxel dosimetry in patients receiving radio-iodine ablation treatment of differentiated thyroid cancer (DTC). METHODS: Eighteen DTC patients were administered 1.11 GBq of 131 I-NaI after near-total thyroidectomy and rhTSH stimulation. Two patients had two remnants, so in total dosimetry was performed for 20 sites. Three SPECT/CT scans were performed for each patient at 1, 2, and 3-7 days after administration. The activity, the remnant mass, and the maximum-voxel activity were determined from these images and from a recovery-coefficient curve derived from experimental phantom measurements. The cumulated activity was estimated using trapezoidal-exponential integration. Finally, the absorbed dose was calculated using S-values for unit-density spheres in whole-remnant dosimetry and S-values for voxels in maximum-voxel dosimetry. RESULTS: The mean absorbed dose obtained from whole-remnant dosimetry was 40 Gy (range 2-176 Gy) and from maximum-voxel dosimetry 34 Gy (range 2-145 Gy). For any given patient, the activity concentrations for each of the three time-points were approximately the same for the two methods. The effective half-lives varied (R = 0.865), mainly due to discrepancies in estimation of the longer effective half-lives. On average, absorbed doses obtained from whole-remnant dosimetry were 1.2 ± 0.2 (1 SD) higher than for maximum-voxel dosimetry, mainly due to differences in theS-values. The method-related differences were however small in comparison to the wide range of absorbed doses obtained in patients. CONCLUSIONS: Simple and consistent procedures for SPECT/CT based whole-volume and maximum-voxel dosimetry have been described, both based on experimentally determined recovery coefficients. Generally the results from the two approaches are consistent, although there is a small, systematic difference in the absorbed dose due to differences in the S-values, and some variability due to differences in the estimated effective half-lives, especially when the effective half-life is long. Irrespective of the method used, the patient absorbed doses obtained span over two orders of magnitude.


Subject(s)
Iodine Radioisotopes/administration & dosage , Radiometry/methods , Single Photon Emission Computed Tomography Computed Tomography/methods , Thyroid Neoplasms/diagnostic imaging , Thyroid Neoplasms/radiotherapy , Calibration , Female , Humans , Male , Phantoms, Imaging , Radiometry/instrumentation , Radiotherapy Dosage , Radiotherapy, Adjuvant/methods , Single Photon Emission Computed Tomography Computed Tomography/instrumentation , Sodium Iodide/administration & dosage , Thyroid Neoplasms/surgery , Thyroidectomy , Time Factors , Treatment Outcome
10.
Ann Nucl Med ; 28(10): 986-93, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25284690

ABSTRACT

OBJECTIVE: Radioiodide is commonly used to diagnose and treat hyperthyroidism and thyroid carcinoma. However, we could not find any experimental data that strictly compared the biodistribution and thyroid uptake of radioactive iodide between the oral and intravenous (iv) routes with time. This prompted us to compare (123)I biodistribution and thyroid uptake to clarify the differences between oral and iv bolus administration in rats. METHODS: The rats were divided into two groups, A and B (n = 5, each). In the first imaging experiment, Na(123)I solution (35 MBq/200 µL) was administered as a bolus to the rats orally in group A and intravenously in group B. Two weeks later, the second imaging experiment was performed as a crossover experiment. (123)I biodistribution was evaluated visually and quantitatively with a gamma camera at 10 min, 3, 6, 12, 24, and 48 h after (123)I administration. Thyroid uptake was compared between oral and iv groups. Correlation of (123)I thyroid uptake and whole-body excretion was evaluated. The area under the curve (AUC) of thyroid uptake was also calculated. RESULTS: (123)I biodistribution differed visually during 6 h between the two groups. (123)I thyroid uptake was significantly higher in the iv group at 10 min (P < 0.05) and in the oral group at 6 or more hour time points (P < 0.005-P < 0.0001) and peaked at 12 h in both groups (oral: 24.4 ± 2.8 %ID, iv: 15.2 ± 2.8 %ID). (123)I thyroid uptake showed significant inverse correlations with whole-body excretion from 6 h (r = -0.799, P < 0.0001), and thereafter [12 h (r = -0.957, P < 0.0001), 24 h (r = -0.905, P < 0.0001) and 48 h (r = -0.893, P < 0.0001)], respectively. (123)I whole-body excretion was significantly higher in the iv group at each time point (P < 0.0001). The AUC of (123)I thyroid uptake was 1.6 times higher in the oral group than the iv group. CONCLUSIONS: These results suggest that radioiodide accumulates in the rat thyroid more effectively by oral than iv administration probably due to slower and lower (123)I clearance from the body in the oral administration when administered in a bolus fashion.


Subject(s)
Iodine Radioisotopes/administration & dosage , Radiopharmaceuticals/administration & dosage , Sodium Iodide/administration & dosage , Thyroid Gland/diagnostic imaging , Administration, Oral , Animals , Area Under Curve , Cross-Over Studies , Injections, Intravenous , Iodine Radioisotopes/pharmacokinetics , Male , Radionuclide Imaging/instrumentation , Radiopharmaceuticals/pharmacokinetics , Random Allocation , Rats, Wistar , Sodium Iodide/pharmacokinetics , Stomach/diagnostic imaging , Time Factors
11.
J Immunol ; 191(10): 4940-9, 2013 Nov 15.
Article in English | MEDLINE | ID: mdl-24098053

ABSTRACT

NOD.H-2h4 mice given NaI in their drinking water develop iodine-accelerated spontaneous autoimmune thyroiditis (ISAT) with chronic inflammation of the thyroid by T and B cells and production of anti-mouse thyroglobulin (MTg) autoantibody. CD28(-/-) NOD.H-2h4 mice, which have reduced numbers of CD4(+)Foxp3(+) regulatory T cells (Tregs), were developed to examine the role of Tregs in ISAT development. CD28(-/-) NOD.H2-h4 mice develop more severe ISAT than do wild-type (WT) mice, with collagen deposition (fibrosis) and low serum T4. CD28(-/-) mice have increased expression of proinflammatory cytokines IFN-γ and IL-6, consistent with increased mononuclear cell infiltration and tissue destruction in thyroids. Importantly, transferring purified CD4(+)Foxp3(+) Tregs from WT mice reduces ISAT severity in CD28(-/-) mice without increasing the total number of Tregs, suggesting that endogenous Tregs in CD28(-/-) mice are functionally ineffective. Endogenous CD28(-/-) Tregs have reduced surface expression of CD27, TNFR2 p75, and glucocorticoid-induced TNFR-related protein compared with transferred CD28(+/+) Tregs. Although anti-MTg autoantibody levels generally correlate with ISAT severity scores in WT mice, CD28(-/-) mice have lower anti-MTg autoantibody responses than do WT mice. The percentages of follicular B cells are decreased and those of marginal zone B cells are increased in spleens of CD28(-/-) mice, and they have fewer thyroid-infiltrating B cells than do WT mice. This suggests that CD28 deficiency has direct and indirect effects on the B cell compartment. B cell-deficient (B(-/-)) NOD.H-2h4 mice are resistant to ISAT, but CD28(-/-)B(-/-) mice develop ISAT comparable to WT mice and have reduced numbers of Tregs compared with WT B(-/-) mice.


Subject(s)
B-Lymphocytes/immunology , CD28 Antigens/deficiency , T-Lymphocytes, Regulatory/immunology , Thyroiditis, Autoimmune/immunology , Animals , Autoantibodies/immunology , CD4 Antigens/metabolism , Fibrosis/immunology , Forkhead Transcription Factors/metabolism , Inflammation , Interferon-gamma/biosynthesis , Interleukin-6/biosynthesis , Lymphocyte Count , Mice , Mice, Inbred NOD , Mice, Knockout , Receptors, Tumor Necrosis Factor, Type II/metabolism , Sodium Iodide/administration & dosage , Thyroglobulin/immunology , Thyroid Gland/immunology , Thyroiditis, Autoimmune/chemically induced , Thyroxine/blood , Tumor Necrosis Factor Receptor Superfamily, Member 7/metabolism
12.
Oncol Rep ; 29(4): 1666-70, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23404348

ABSTRACT

Gene therapy using human sodium iodide symporter (hNIS) and radioiodine has been considered promising in a variety of gene therapy trials. However, the optimal timing of radioiodine application following hNIS gene transfer remains unknown. The present study aimed to investigate the serial expression of hNIS following adenovirus-mediated hNIS gene transfer into anaplastic thyroid carcinoma (ARO) to determine the optimal timing of radioiodine application. Recombinant adenovirus encoding the hNIS gene (rAd-hNIS) was generated using a homologous recombination reaction. The iodine uptake of rAd-hNIS­transfected ARO cells gradually increased until 120 min post­125I application but the fold increase, reflecting the relative uptake of rAd-hNIS­transfected compared to non­transfected ARO cells, reached plateau at 60 min post­125I application. For the in vivo analysis, rAd-hNIS was injected intratumorally into ARO cell xenografts in the thighs of nude mice (n=12). Two, 3, 4 and 6 days after rAd-hNIS injection, γ­scintigraphic images were obtained 60 min following injection of 5.5 MBq of 131I intraperitoneally. Treated/non-treated (T/NT) xenograft count ratios were the highest at day 2 post­rAd-hNIS injection (2.85±0.61), and gradually decreased thereafter (2.54±0.65, 2.31±0.42 and 2.18±0.90 at days 3, 4 and 6 post­rAd-hNIS injection, respectively). Real­time polymerase chain reaction (RT-PCR) and immunohistochemical staining demonstrated that hNIS expression was the highest at day 2 following rAd-hNIS injection. In conclusion, the optimal timing for radioiodine administration is day 2 after adenovirus-mediated hNIS gene transfer into anaplastic thyroid carcinoma.


Subject(s)
Sodium Iodide/administration & dosage , Symporters/genetics , Thyroid Neoplasms/genetics , Thyroid Neoplasms/radiotherapy , Adenoviridae , Animals , Cell Line, Tumor , Gene Expression Regulation, Neoplastic/radiation effects , Genetic Therapy , Humans , Iodine Radioisotopes/administration & dosage , Mice , Mice, Nude , Thyroid Carcinoma, Anaplastic , Thyroid Neoplasms/pathology , Transfection , Xenograft Model Antitumor Assays
13.
Br J Radiol ; 85(1012): e76-8, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22457411

ABSTRACT

An 80-year-old male with recurrent thyroid cancer and a percutaneous endoscopic gastrostomy (PEG) tube in situ was referred for radioiodine therapy and was administered 5510 MBq I-131 sodium iodide intravenously. Sequential whole-body images taken over the subsequent 7 days for dosimetric evaluation revealed an area of persistent high uptake in the abdomen. Delayed imaging with single photon emission CT/CT at 15 days post administration revealed this uptake to be at the junction of the PEG tube with the anatomically normal stomach wall. We hypothesise that the PEG tube became contaminated by radioiodine secreted in the gastric mucosa during therapy and this radioactivity subsequently decayed with an increased effective half-life relative to the stomach, leading to the apparent hot spot.


Subject(s)
Gastrostomy/instrumentation , Iodine Radioisotopes/metabolism , Aged, 80 and over , Gastroscopy/methods , Humans , Injections, Intravenous , Iodine Radioisotopes/administration & dosage , Male , Multimodal Imaging , Positron-Emission Tomography , Sodium Iodide/administration & dosage , Thyroid Neoplasms/radiotherapy , Tomography, X-Ray Computed
14.
Radiat Prot Dosimetry ; 151(2): 252-61, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22345216

ABSTRACT

This work aims at assessing the performance of a portable detection system, equipped with an NaI(Tl) scintillation detector for in vivo thyroid monitoring, which was properly calibrated using an anthropomorphic neck phantom. The anthropomorphic physical phantoms commonly used for the efficiency calibration of in vivo counters often present certain limitations regarding the geometry and the activity distribution. Therefore, the feasibility of these detection systems for in vivo monitoring should be assessed whenever possible. To accomplish this assessment, patients to whom (99m)Tc and (123)I marked radiopharmaceuticals have been administered in the framework of nuclear medicine diagnostic procedures were monitored. As the biokinetic models of the administered radiopharmaceuticals are known, the time-dependent activity functions in the critical organs after administration are easily quantified. The measured activities in the thyroid using the NaI(Tl) scintillation detector were compared with the estimated activities using the biokinetic models, in order to reach conclusion about the applicability of the portable scintillation counter for in vivo thyroid monitoring. The state-of-the-art Monte Carlo computer program PENELOPE and two voxel phantoms (male and female) were used to evaluate the overall uncertainties influencing the thyroid monitoring. A computational parametric study was performed to quantify the influence of several parameters in the activity quantification (neck-detector distance, thyroid shape, thyroid size and overlying tissue thickness), which allowed one to gain insight and to better understand the discrepancies between the calculated and measured activities.


Subject(s)
Iodine Radioisotopes , Occupational Exposure , Radiation Monitoring , Sodium Iodide/administration & dosage , Thyroid Gland/radiation effects , Uncertainty , Computer Simulation , Humans , Monte Carlo Method , Phantoms, Imaging , Radiopharmaceuticals , Scintillation Counting , Thyroid Gland/anatomy & histology
15.
Radiat Prot Dosimetry ; 148(2): 143-8, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21307022

ABSTRACT

Current practice for radiation protection associated with (131)I therapy mainly focuses on external and internal exposure caused by physical contamination of the hospital staff, other patients and family members. However, if volatile (131)I is excreted by the treated patients, these individuals could also be exposed through inhalation of (131)I. This study quantifies the amount of volatile (131)I excreted by rats after intravenous administration of metaiodobenzylguanidine (MIBG)-(131)I or Na(131)I, the two most common forms of (131)I therapy. The results indicate that in 4 d following administration, the total excretion of volatile (131)I was 0.036 and 0.17 % of the administered activities of MIBG-(131)I and Na(131)I, respectively. As administered activities for (131)I therapy are typically of the order of 1-10 GBq, the overall excretion of volatile (131)I from a patient can be as high as 20 MBq. As a result, a family member can receive up to 0.07 mSv committed effective dose from inhaling the volatile (131)I excreted by the patient.


Subject(s)
3-Iodobenzylguanidine/administration & dosage , Iodine Radioisotopes/analysis , Iodine Radioisotopes/metabolism , Sodium Iodide/administration & dosage , 3-Iodobenzylguanidine/pharmacokinetics , Animals , Male , Mice , Mice, Hairless , Radiation Protection , Radiometry , Radiopharmaceuticals/administration & dosage , Radiopharmaceuticals/pharmacokinetics , Rats , Sodium Iodide/pharmacokinetics , Tissue Distribution
16.
Br J Nutr ; 107(5): 674-82, 2012 Mar.
Article in English | MEDLINE | ID: mdl-21794198

ABSTRACT

Our previous epidemiological study indicated that excessive intake of iodine could potentially lead to hypothyroidism. In the present study, we aimed to investigate the time and dose effect of iodine intake on serum thyrotropin (thyroid-stimulating hormone, TSH) levels and to explore the non-autoimmune regulation of serum TSH by pituitary type 2 deiodinase (D2). A total of 360 Wistar rats were randomly divided into five groups depending on administered iodine dosages (folds of physiological dose): normal iodine (NI), 3-fold iodine (3HI), 6-fold iodine (6HI), 10-fold iodine (10HI) and 50-fold iodine (50HI). At 4, 8, 12 and 24 weeks after administration of sodium iodide, blood was collected for serum TSH measurement by chemiluminescent immunoassay. Pituitaries were also excised for measurement of TSHß subunit expression, D2 expression and activity, monocarboxylate transporter 8 (MCT8) and thyroid hormone receptor ß2 isoform (TRß2) levels. The results showed that iodine intake of 10HI and 50HI significantly increased pituitary and serum TSH levels from 8 to 24 weeks (P < 0·05 v. NI). Excess iodine had no effect on D2 mRNA or protein expression; however, 10HI and 50HI administration significantly inhibited pituitary D2 activities from 8 to 24 weeks (P < 0·05 v. NI). Iodine had no effect on MCT8 or TRß2 protein levels. We conclude that prolonged high iodine intake inhibits pituitary D2 activity and induces elevation of serum TSH levels. These findings may provide a potential mechanism of iodine excess-induced overt and subclinical hypothyroidism.


Subject(s)
Diet/adverse effects , Iodide Peroxidase/metabolism , Iodine/adverse effects , Pituitary Gland/enzymology , Thyrotropin/blood , Animals , Female , Gene Expression Regulation , Hypothyroidism/blood , Hypothyroidism/etiology , Hypothyroidism/metabolism , Hypothyroidism/pathology , Immunohistochemistry , Iodide Peroxidase/genetics , Iodine/administration & dosage , Male , Pituitary Gland/metabolism , Pituitary Gland/pathology , Protein Processing, Post-Translational , RNA, Messenger/metabolism , Random Allocation , Rats , Rats, Wistar , Severity of Illness Index , Sodium Iodide/administration & dosage , Sodium Iodide/adverse effects , Thyrotropin, beta Subunit/genetics , Thyrotropin, beta Subunit/metabolism , Time Factors , Iodothyronine Deiodinase Type II
17.
Pesqui. vet. bras ; 31(9): 747-750, set. 2011. ilus
Article in Portuguese | LILACS, VETINDEX | ID: lil-602165

ABSTRACT

Descreve-se um surto de abscesso mandibular em ovelhas da raça Bergamácia no município de Botucatu, estado de São Paulo. Do rebanho de 120 animais, 35 apresentaram aumento de volume mandibular com a presença de nódulos únicos, de consistência pétrea, de diferentes tamanhos, fistulados ou não e sem indicativos de inflamação dos tecidos moles adjacentes. Os animais eram criados em pasto de Panicum maximum cv. Tanzânia com água e sal mineral ad libitum e everminados, via oral, com pistolas dosificadoras. O material para diagnóstico microbiológico e antibiograma foi coletado de cinco animais acometidos, por punção e aspiração dos nódulos. Dos 35 animais acometidos, 19 foram submetidos ao exame radiográfico, um ao exame tomográfico e outro à biópsia óssea da região submandibular. O único ovino que morreu, encontrava-se em estado de caquexia provavelmente devido à localização do aumento de volume que afetou a implantação dos dentes molares daquela região impedindo a apreensão e mastigação adequadas levando a perda da condição corporal e morte. Ao exame necroscópico, observaram-se áreas de necrose caseosa na mandíbula direita de onde isolou-se Pseudomonas aeruginosa. O tratamento utilizado foi baseado na aplicação de iodeto de sódio a 10 por cento por via intramuscular e antibioticoterapia segundo antibiograma com enrofloxacina por via intramuscular, porém com pouca eficácia. Diante do quadro clínico, dos dados de anamnese, da localização das lesões no tecido ósseo mandibular, do resultado do cultivo microbiológico, das alterações radiográficas e tomográficas foi feito o diagnóstico de abscesso mandibular causado por Pseudomonas aeruginosa.


We describe an outbreak of mandibular abscess in Bergamácia sheep from the municipality of Botucatu, São Paulo, Brazil. In a herd of 120 sheep, 35 showed an increase of the mandibular volume with presence of a single nodule of stony consistency and different sizes, often fistulated but with no signs of inflammation in the surrounding soft tissues. The sheep were raised on a Panicum maximum cv. Tanzania pasture, with water and mineral salt ad libitum, and were treated orally against parasites with drenching pistols. Material for microbiological diagnosis and antibiogram was collected from the nodules of five affected sheep, through puncture and aspiration. From 35 affected sheep, 19 were submitted to radiographic examination, one was submitted to computer tomography and another to bone biopsy of the submandibular region. The only sheep that died was in a state of cachexia, probably due to the location of the volume increase which affected the molar hindering apprehension and appropriate chewing. Necropsy revealed areas of caseous necrosis in the jaw, from where Pseudomonas aeruginosa was isolated. The sheep were treated with intramuscular application of 10 percent sodium iodide and the antobiotgic enrofloxacin, but with little efficacy. Based on the clinical data from medical records, the location of lesions in the jaw bone, the result of microbiological culture, radiographic and computer tomography, the diagnosis of mandibular abscesses due to Pseudomonas aeruginosa infection was made.


Subject(s)
Animals , Pseudomonas aeruginosa , Sheep , Disease Outbreaks/veterinary , Abscess/veterinary , Sodium Iodide/administration & dosage , Diagnosis , Necrosis/veterinary
18.
Graefes Arch Clin Exp Ophthalmol ; 248(11): 1639-46, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20496151

ABSTRACT

BACKGROUND: Environmental oxidative stress changing the properties of the tear fluid can lead to keratoconjunctivitis sicca (dry eye syndrome). The aim of this study was to determine whether iodide iontophoresis influences the antioxidative capacity (ACW = water soluble antioxidative capacity) of the tear fluid, and to compare iodide iontophoresis with other balneotherapeutic measures. METHODS: This prospective study evaluated 92 patients in four groups. Twenty-four patients were treated with iodide iontophoresis, 24 with other balneotherapeutic methods. Twenty-five patients received iodide iontophoresis combined with other balneotherapeutic methods and 21 persons received no treatment (control). Unstimulated tear fluid, serum and urine were collected. ACW was determined photochemically in tear fluid and serum; iodine was measured in urine photometrically. RESULTS: Iodide iontophoresis increases the ACW of the tear fluid but not the ACW of the serum. Other iodine therapies increase the ACW in serum but not in tear fluid. Iodine excretion in urine was increased in all treated groups compared to the control. CONCLUSION: The increase of ACW in tear fluid after iodide iontophoresis can support the defense mechanism of the eye against oxidative influence effects, which may alleviate the symptoms of keratoconjunctivitis sicca.


Subject(s)
Antioxidants/metabolism , Balneology , Iontophoresis/methods , Keratoconjunctivitis Sicca/drug therapy , Sodium Iodide/administration & dosage , Tears/metabolism , Humans , Keratoconjunctivitis Sicca/metabolism , Oxidative Stress , Prospective Studies
19.
Radiol. bras ; 42(2): 97-101, mar.-abr. 2009. graf, tab
Article in Portuguese | LILACS | ID: lil-513150

ABSTRACT

OBJETIVO: Avaliar a mudança no perfil e abordagem dos pacientes com doença de Graves submetidos a dose terapêutica de radioiodo. MATERIAIS E MÉTODOS: Avaliamos, retrospectivamente, 226 pacientesportadores de doença de Graves submetidos a dose terapêutica de radioiodo entre janeiro de 1990 e dezembro de 2001. O período de 12 anos foi dividido em três períodos de 4 anos para fins de análise estatística,sendo comparadas variáveis clínicas e laboratoriais nos períodos descritos. RESULTADOS: Constatamos que o número de pacientes encaminhados para a dose terapêutica, assim como o percentual de pacientes do sexo feminino (de 62% para 86%; p = 0,005), tiveram incremento significativo. Houve aumento significativo no percentual de pacientes em uso de metimazol previamente à dose terapêutica (de 9,1% para 35,6%;p = 0,03). A dose média de iodo administrada também teve incremento significativo (de 7,6 mCi para 12,7mCi; p = 0,000003), com reflexo direto em um maior percentual de pacientes curados (de 55,6% para 83,7%; p = 0,004) um ano pós-dose terapêutica. CONCLUSÃO: A dose terapêutica de radioiodo tem sido um método cada vez mais aceito nos pacientes com doença de Graves e a dose administrada tem sido cada vez maior, no intuito de cura permanente e diminuição das chances de recidiva.


OBJECTIVE: To evaluate the changes in clinical parameters and in the approach to patients submitted to radioiodine therapy for Graves' disease. MATERIALS AND METHODS: Dossiers of 226 patients submitted to radioiodine therapy for Graves' disease in the period between January 1990 and December 2001 were retrospectively evaluated. For the purposes of statistical analysis, the 12-year period was subdivided into three periods of 4 years, with a comparison of clinical and laboratory variables in these periods. RESULTS: The authors have observed that the total number of patients referred for radioiodine therapy as well as the percentage of female patients presented a significant increase (from 62% to 86%; p = 0.005). The percentage of patients pretreated with methimazole before radioiodine therapy increased significantly (from 9.1% to35.6%; p = 0.03). The mean radioiodine dose delivered has also presented a significant increase (from 7.6 mCi to 12.7 mCi; p = 0.000003) with a direct reflection on a higher percentage of patients cured one year after the radioiodine therapy (from 55.6% to 83.7%; p = 0.004). CONCLUSION: Radioiodine therapy has increasingly been accepted for treatment of patients with Graves' disease and the doses delivered have increased to achieve a permanent cure as well as a reduction of the chances of recurrence.


Subject(s)
Humans , Female , Graves Disease , Sodium Iodide/administration & dosage , Sodium Iodide/therapeutic use , Graves Disease/drug therapy , Hyperthyroidism , Iodine Radioisotopes , Methimazole , Retrospective Studies
20.
J Autoimmun ; 29(2-3): 195-202, 2007.
Article in English | MEDLINE | ID: mdl-17826032

ABSTRACT

NOD-H2(h4) mice, which express I-A(k) on the NOD background, spontaneously develop autoimmune thyroiditis, a model of Hashimoto thyroiditis in humans, by adding iodide in the drinking water. Parental NOD mice have previously been shown to have intrinsic numerical abnormalities in peripheral lymphocytes and lymphocyte subpopulations such as CD4(+)CD25(+) naturally occurring regulatory T cells (Treg). Therefore we first investigated whether the similar abnormalities exist in NOD-H2(h4) mice. We observed that, compared with other non-autoimmune disease prone BALB/c and C57BL/6 mice, NOD-H2(h4) mice have lower numbers of splenocytes, CD3(+)T, CD4(+)T and CD8(+)T cells but the ratios of Treg to CD4(+)T cells were comparable. Increasing the numbers of peripheral lymphocytes by Complete Freund's Adjuvant immunization or splenocyte transfer did not affect development of thyroiditis, indicating that lymphopenia does not play a critical role in the pathogenesis of thyroiditis. We next examined the significance of Treg by depleting this lymphocyte subset with anti-CD25 antibody. Treg depletion, performed 4days before the administration of NaI water for 8 weeks, significantly exacerbated thyroiditis (p<0.01). Anti-thyroglobulin antibody titers also increased by Treg depletion (p<0.01) without changing the IgG2b to IgG1 ratios. In addition, expression levels of mRNA for IFN-gamma and IL-4 were enhanced in parallel. However, T(4) levels were similar between antibody-treated and untreated groups. Additional anti-CD25 administration at 3 weekly intervals did not influence these results. These data, together with previous studies on other mouse models of inducible thyroiditis and Graves' disease, indicate the role played by Treg in keeping anti-thyroid autoimmune reaction in check in experimental autoimmune thyroid diseases.


Subject(s)
Lymphopenia/immunology , T-Lymphocytes, Regulatory/immunology , Thyroiditis, Autoimmune/immunology , Animals , Autoantibodies/analysis , Autoantibodies/immunology , Interleukin-2 Receptor alpha Subunit/analysis , Interleukin-2 Receptor alpha Subunit/immunology , Lymphocyte Count , Mice , Mice, Inbred NOD , Sodium Iodide/administration & dosage , T-Lymphocytes, Regulatory/metabolism , Thyroglobulin/immunology , Thyroid Gland/cytology , Thyroid Gland/immunology , Thyroid Gland/metabolism , Thyroiditis, Autoimmune/chemically induced , Thyroiditis, Autoimmune/metabolism , Thyroxine/blood , Thyroxine/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...